These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28640208)

  • 1. Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury.
    McEuen K; Borlak J; Tong W; Chen M
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury.
    Chen M; Borlak J; Tong W
    Hepatology; 2013 Jul; 58(1):388-96. PubMed ID: 23258593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model.
    Chen M; Tung CW; Shi Q; Guo L; Shi L; Fang H; Borlak J; Tong W
    Arch Toxicol; 2014 Jul; 88(7):1439-49. PubMed ID: 24958025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury.
    Yu K; Geng X; Chen M; Zhang J; Wang B; Ilic K; Tong W
    Drug Metab Dispos; 2014 Apr; 42(4):744-50. PubMed ID: 24464804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties.
    Yucha RW; He K; Shi Q; Cai L; Nakashita Y; Xia CQ; Liao M
    Toxicol Sci; 2017 Jun; 157(2):487-499. PubMed ID: 28369588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of DILI Predictive Hypotheses in Early Drug Development.
    Chan R; Benet LZ
    Chem Res Toxicol; 2017 Apr; 30(4):1017-1029. PubMed ID: 28257576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury.
    Yano A; Oda S; Fukami T; Nakajima M; Yokoi T
    Toxicol Lett; 2014 Jul; 228(1):13-24. PubMed ID: 24747151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals.
    Lammert C; Einarsson S; Saha C; Niklasson A; Bjornsson E; Chalasani N
    Hepatology; 2008 Jun; 47(6):2003-9. PubMed ID: 18454504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced liver injury: what was new in 2013?
    Chalhoub WM; Sliman KD; Arumuganathan M; Lewis JH
    Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):959-80. PubMed ID: 24746272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
    Norman BH
    J Med Chem; 2020 Oct; 63(20):11397-11419. PubMed ID: 32511920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Machine Learning Algorithms for Predicting Drug-Induced Liver Injury (DILI).
    Minerali E; Foil DH; Zorn KM; Lane TR; Ekins S
    Mol Pharm; 2020 Jul; 17(7):2628-2637. PubMed ID: 32422053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs.
    Leeson PD
    Chem Res Toxicol; 2018 Jun; 31(6):494-505. PubMed ID: 29722540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury.
    Thakkar S; Chen M; Fang H; Liu Z; Roberts R; Tong W
    Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):31-38. PubMed ID: 28931315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiosyncratic Drug Induced Liver Injury, Cytochrome P450, Metabolic Risk Factors and Lipophilicity: Highlights and Controversies.
    Teschke R; Danan G
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles.
    Zhang J; Doshi U; Suzuki A; Chang CW; Borlak J; Li AP; Tong W
    Chem Biol Interact; 2016 Aug; 255():3-11. PubMed ID: 26581450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.
    Gómez-Lechón MJ; Tolosa L; Donato MT
    J Appl Toxicol; 2016 Jun; 36(6):752-68. PubMed ID: 26691983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced liver injury: the role of drug metabolism and transport.
    Corsini A; Bortolini M
    J Clin Pharmacol; 2013 May; 53(5):463-74. PubMed ID: 23436293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting and preventing acute drug-induced liver injury: what's new in 2010?
    Liss G; Rattan S; Lewis JH
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1047-61. PubMed ID: 20615079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events.
    Lammert C; Bjornsson E; Niklasson A; Chalasani N
    Hepatology; 2010 Feb; 51(2):615-20. PubMed ID: 19839004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Decision Forest Models for Prediction of Drug-Induced Liver Injury in Humans Using A Large Set of FDA-approved Drugs.
    Hong H; Thakkar S; Chen M; Tong W
    Sci Rep; 2017 Dec; 7(1):17311. PubMed ID: 29229971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.